Turning Point Therapeutics Inc. (TPTX) Misses Q3 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/15/2026

1. SPY
2. BAC
3. CRWV
4. BLK
5. RKLB
6. RXRX
7. NOW
8. ACN
9. PAG
10. MS

Go back to Turning Point Therapeutics Inc. (TPTX) Misses Q3 EPS by 7c

Turning Point Therapeutics Reports Third-Quarter Financial Results, Provides Operational Updates

November 9, 2021 4:01 PM EST

Updated Preliminary Clinical Data Presented for Lead Drug Candidate Repotrectinib and Elzovantinib at the AACR-NCI-EORTC ConferenceMultiple FDA Interactions Anticipated in Q4 2021 and 1H 2022 for Repotrectinib and ElzovantinibCash, Cash Equivalents, and Marketable Securities of $1.0 Billion Expected to Fund Current Operations into 2024

SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported financial results for the third quarter ended September 30, 2021 and provided... More